Cardiff Oncology Inc expected to post a loss of 15 cents a share - Earnings Preview

Cardiff Oncology

05/08/2021 21:37

* Cardiff Oncology Inc  CRDF.OQ   CRDF.O  is expected to show a
rise in quarterly revenue when it reports results on August 9
(estimated). 
* The San Diego, California-based company is expected to report 
 a 257.7% increase in revenue to $152.5 thousand from $42.63
thousand a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Cardiff Oncology Inc is
for a loss of 15 cents per share. For the same quarter last
year, the company reported a loss of 51 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Cardiff
Oncology Inc is $25​, about 80% above​ its last closing price
of $5.01. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.16       -0.15      -0.14     Beat    5.1
 Dec. 31 2020  -0.15       -0.14      -0.19     Missed  -35.7
 Sep. 30 2020  -0.19       -0.19      -0.19     Met     -1.8​
 Jun. 30 2020  -0.24       -0.24      -0.51     Missed  -112.5
 ​​            ​                                        ​
 Dec. 31 2019  -0.79       -0.57      -0.51     Beat    11.3​
 Sep. 30 2019  -0.84       -0.84      -0.71     Beat    15.5
 Jun. 30 2019              -0.53      -0.79     Missed  -49.1
 This summary was machine generated August 5 at 20:37 GMT.  All
figures in US dollars unless otherwise stated